GFGianluca Andri Florineth

Gianluca Andri Florineth

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Gianluca Andri Florineth has a total of 30 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Bivariate Multiscale Sample Entropy of Frontoparietal-Subgenual ACC Dynamics in Depression During Accelerated TMS at 7 T

    by Niklaus Denier, Matthias Grieder, Kay Jann, Pascal Borel, Stefan Dendorfer, Gianluca Andri Florineth, Kristina Adorjan, Andrea Federspiel, Roland Wiest, Leila Maria Soravia, et al.

    Objective: To examine whether longitudinal changes in frontoparietal (FP) - subgenual anterior cingulate cortex (sgACC) joint temporal complexity differ between sgACC hemispheres in patients undergoing accelerated TMS (aTMS) and untreated healthy controls. Methods: Twenty-four patients with current depressive episodes and fifteen healthy controls underwent 7T resting-state fMRI at baseline and follow-up. Patients received aTMS localized to the left DLPFC using Beam-F3. The same bilateral FP time series was paired separately with left and right sgACC time series. Bivariate multiscale sample entropy (bMSE) across scale factors a1-a10 was summarized by trapezoidal integration as a complexity index (bMSE-CI). The primary test was the Group x Time x sgACC Hemisphere interaction in a mixed repeated-measures ANOVA. Scale-specific interactions and clinical Spearman correlations were evaluated with Benjamini-Hochberg false discovery rate correction. Change scores were follow-up minus baseline. Results: The bMSE-CI Group x Time x Hemisphere interaction was significant (F(1,37) = 6.043, p = 0.0188, partial Eta squared = 0.140). Mean left/right bMSE-CI changes were -0.286/+0.124 in patients and +0.323/+0.112 in controls. Of ten scale-specific three-way interactions, only a2 survived FDR correction (q = 0.0435). No baseline or change-score bMSE-MADRS association survived the specified FDR corrections. A random-intercept-only mixed-model sensitivity analysis did not reach statistical significance for the three-way interaction (p = 0.0718). Conclusion: FP-sgACC joint temporal complexity showed hemisphere-dependent longitudinal differences between patients undergoing aTMS and healthy controls. These exploratory findings motivate further evaluation of bMSE as a candidate measure of longitudinal neural change in depression. Independent replication, more precise reliability estimates, and prospective validation of clinical relevance are needed.

  • Open Access

    Efficacy and safety of psilocybin-assisted therapy for alcohol use disorder: A systematic review and meta-analysis

    by Gianluca A. Florineth, Anna L. Boeker, Tobias Bracht, Alexander Wopfner, Niklaus Denier, Kristina Adorjan, Felix Müller, Leila M. Soravia

    Background: Psilocybin-assisted therapy (PAT) has emerged as a promising intervention for alcohol use disorder (AUD), yet contemporary clinical evidence has not been systematically synthesized to validate its clinical utility and safety profile. Methods: Contemporary clinical trials of PAT for AUD were identified systematically from PubMed, PsycINFO, and Scopus by two independent reviewers. Random-effects meta-analyses were conducted to synthesize within-group pre–post changes and between-group differences from randomized controlled trials (RCTs). Primary outcomes included continuous drinking measures and abstinence rates; secondary outcomes included adverse events (AEs). Results: Six trials ( N = 202) met inclusion criteria (3 RCTs). PAT produced significant within-group reductions across all drinking outcomes that were sustained at mid- to long-term follow-up (4–28 weeks). Compared to controls, psilocybin demonstrated moderate short-term advantages for drinks per day (standardized mean differences (SMD) = 0.48; p = 0.004), percent drinking days (SMD = 0.50; p = 0.009), and percent heavy drinking days (SMD = 0.39; p = 0.020). At mid- to long-term follow-up, only percent drinking days remained significantly superior (SMD = 0.41; p = 0.032). Psilocybin-treated patients had significantly higher odds of maintaining abstinence compared to controls (OR = 2.78; p = 0.029). AEs were predominantly mild and transient. Conclusions: Current evidence for PAT in AUD is mixed but suggests preliminary signals of efficacy for reducing alcohol consumption and increasing the odds of maintaining long-term abstinence. The intervention was well-tolerated with a favorable safety profile, supporting its potential as a novel treatment option.

  • Open Access

    Beyond the substance: A systematic review of psychological treatment frameworks in psychedelic-assisted therapy

    by Gianluca A. Florineth, Anna L. Boeker, Felix Müller, Tobias Bracht, Niklaus Denier, Antonia C. Jung, Alexander Wopfner, Kristina Adorjan, Leila M. Soravia

    Background: Classic psychedelics show potential for treating psychiatric disorders, yet the psychological framework of psychedelic-assisted therapy (PAT) remains underspecified. As regulatory approval approaches, defining the contribution of psychological interventions to clinical outcomes is critical for both mechanism inference and implementation. Objectives: To systematically review the structure, content, and duration of psychological interventions in contemporary clinical trials of serotonergic psychedelics for psychiatric symptoms, and to map the state of current approaches to inform future trial designs. Design: A systematic review following PRISMA guidelines. Data Sources and Methods: A systematic literature search was performed across PubMed, PsycINFO, and SCOPUS. Inclusion criteria targeted clinical trials administering serotonergic psychedelics (lysergic acid diethylamide (LSD), psilocybin, or dimethyltryptamine (DMT)) for psychiatric symptoms. Two reviewers independently screened studies and extracted data on dosing frameworks and psychological interventions. Results: We identified 44 trials (1,537 participants), covering depressive symptoms (n=20), substance use disorders (n=8), life-threatening illness-related distress (n=8), anxiety disorders (n=2), and other indications (n=6). Nearly all trials followed a three-phase preparation–dosing–integration structure, and dosing regimens showed increasing standardization. Psychological support, however, varied substantially: non-dosing sessions ranged from zero to 17, and frameworks spanned minimal/non-directive support to manualized established approaches (e.g., ACT, CBT). These interventions were frequently tailored by clinical indication, such as utilizing motivational enhancement for substance use disorders and addressing existential themes for life-threatening illnesses. Conclusion: Despite convergence on a shared procedural structure, PAT protocols remain highly heterogeneous in psychological embedding and orientation, reflecting tension between clinical depth and scalability. Because psychedelics are typically administered within a psychological context, this heterogeneity complicates efforts to isolate pharmacological from contextual effects, and existing evidence suggests the therapeutic context may itself moderate safety and efficacy. Advancing the field requires dismantling trials isolating psychological components and applying the same empirical rigor to psychotherapeutic as to pharmacological parameters.

  • Open Access

    Blinding integrity in psychedelic research: Evidence from a comparative randomized controlled trial of psilocybin, MDMA, and methylphenidate in healthy volunteers

    by L. Belinger, N.M. Rieser, E.J.E. Engeli, L. Becciolini, M. Clamote, M. Pribis, F. Saissi, G.A. Florineth, N.L. Hehl, M. Herdener, et al.